EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.36 Million USD | -93.88% |
| 2022 | 22.34 Million USD | 5.98% |
| 2021 | 21.08 Million USD | 20666.32% |
| 2020 | -102.5 Thousand USD | -101.02% |
| 2019 | 10.03 Million USD | 0.0% |
| 2017 | -1.91 Million USD | -127.28% |
| 2016 | 7.03 Million USD | 287.78% |
| 2015 | -3.74 Million USD | 63.66% |
| 2014 | -10.3 Million USD | -303.4% |
| 2013 | 5.06 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.49 Million USD | 1.16% |
| 2024 Q1 | 1.47 Million USD | 7.85% |
| 2024 Q3 | 1.49 Million USD | 0.14% |
| 2023 Q3 | 988.12 Thousand USD | 16.97% |
| 2023 Q4 | 1.36 Million USD | 38.44% |
| 2023 FY | 1.36 Million USD | -93.88% |
| 2023 Q1 | 714.88 Thousand USD | -96.8% |
| 2023 Q2 | 844.74 Thousand USD | 18.17% |
| 2022 Q3 | 21.75 Million USD | -0.17% |
| 2022 FY | 22.34 Million USD | 5.98% |
| 2022 Q4 | 22.34 Million USD | 2.69% |
| 2022 Q1 | 21.08 Million USD | 0.02% |
| 2022 Q2 | 21.79 Million USD | 3.37% |
| 2021 Q1 | -202.5 Thousand USD | 0.0% |
| 2021 Q4 | 21.07 Million USD | 0.0% |
| 2021 FY | 21.08 Million USD | 20666.32% |
| 2021 Q2 | -600 Thousand USD | -196.3% |
| 2021 Q3 | 21.07 Million USD | 3612.65% |
| 2020 FY | -102.5 Thousand USD | -101.02% |
| 2019 FY | 10.03 Million USD | 0.0% |
| 2017 Q1 | 5.22 Million USD | -23.88% |
| 2017 FY | -1.91 Million USD | -127.28% |
| 2017 Q2 | 5.22 Million USD | 0.0% |
| 2017 Q4 | 8.38 Million USD | 0.0% |
| 2016 Q1 | -20.08 Million USD | -10.87% |
| 2016 Q3 | 7.06 Million USD | 0.5% |
| 2016 Q2 | 7.03 Million USD | 135.0% |
| 2016 FY | 7.03 Million USD | 287.78% |
| 2016 Q4 | 6.86 Million USD | -2.81% |
| 2015 Q1 | -5.1 Million USD | -266.97% |
| 2015 FY | -3.74 Million USD | 63.66% |
| 2015 Q4 | -18.11 Million USD | 2.43% |
| 2015 Q3 | -18.56 Million USD | -395.9% |
| 2015 Q2 | -3.74 Million USD | 26.73% |
| 2014 Q4 | 3.06 Million USD | 126.54% |
| 2014 Q1 | 17.82 Million USD | -10.03% |
| 2014 Q2 | -10.3 Million USD | -157.8% |
| 2014 Q3 | -11.52 Million USD | -11.91% |
| 2014 FY | -10.3 Million USD | -303.4% |
| 2013 FY | 5.06 Million USD | 0.0% |
| 2013 Q2 | 12.02 Million USD | 0.0% |
| 2013 Q3 | 5.79 Million USD | -51.81% |
| 2013 Q4 | 19.81 Million USD | 242.04% |
| 2012 Q3 | 4320.68 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 104525.267% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 75.781% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 96.803% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 648.021% |
| Rebus Holdings, Inc. | 305 Thousand USD | -348.515% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 121.698% |
| Qrons Inc. | 351.42 Thousand USD | -289.262% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -119.802% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 96.85% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 6803.112% |
| Skye Bioscience, Inc. | -5.72 Million USD | 123.91% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 91.322% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 66.781% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -240.419% |
| SQZ Biotechnologies Company | -36.23 Million USD | 103.775% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 38.991% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -47.54% |
| Mesoblast Limited | 55.85 Million USD | 97.551% |
| Marizyme, Inc. | 18.56 Million USD | 92.633% |
| Genus plc | 190.6 Million USD | 99.282% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 38.816% |
| Pharming Group N.V. | 109.8 Million USD | 98.754% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -59.022% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -12.693% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -101.172% |
| ContraFect Corporation | -6.02 Million USD | 122.701% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -916.029% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -18.395% |
| IMV Inc. | 7.67 Million USD | 82.166% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 75.136% |
| MultiCell Technologies, Inc. | 90.04 USD | -1519192.537% |
| ONE Bio Corp. | 9.04 Million USD | 84.868% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 286.378% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 89.433% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | 4.06 Million USD | 66.306% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 95.523% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -35.75% |
| Biomind Labs Inc. | 711.4 Thousand USD | -92.292% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.741% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 31.581% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 89.318% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -280.298% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -878.492% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -6785.645% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 37.875% |
| GB Sciences, Inc. | 1.74 Million USD | 21.71% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 844.32% |
| HST Global, Inc. | 96.79 Thousand USD | -1313.295% |
| CSL Limited | 10.52 Billion USD | 99.987% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -563.365% |
| Halberd Corporation | 144.72 Thousand USD | -845.247% |
| Enzolytics Inc. | 981.65 Thousand USD | -39.353% |
| Agentix Corp. | 37.63 Thousand USD | -3535.224% |
| Resverlogix Corp. | 6.45 Million USD | 78.794% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 303.238% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.067% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.91% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 80.654% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 49.496% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 115.475% |
| AVAX Technologies, Inc. | -5.9 Million USD | 123.173% |
| Zenith Capital Corp. | 10.06 Thousand USD | -13492.717% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.129% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -582.511% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 42.668% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -731.548% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 7567.906% |
| Kadimastem Ltd | -253.1 Thousand USD | 640.482% |
| Helix BioMedix, Inc. | -2.57 Million USD | 153.228% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 93.253% |
| BioStem Technologies, Inc. | 4.47 Million USD | 69.41% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -579.724% |
| LadRx Corporation | -2.03 Million USD | 167.174% |
| Cell Source, Inc. | 9.23 Million USD | 85.182% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -115.372% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -115.372% |
| NovAccess Global Inc. | 2.17 Million USD | 37.205% |
| Affymax, Inc. | -5.59 Million USD | 124.441% |
| Itoco Inc. | 228.3 Thousand USD | -499.186% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -905.942% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 72.403% |
| Mobile Lads Corp. | 484.23 Thousand USD | -182.503% |
| CytoDyn Inc. | 20.26 Million USD | 93.249% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 211532.921% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 14859.612% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 82.248% |
| SYBLEU INC | 473.71 Thousand USD | -188.776% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 69.308% |
| International Stem Cell Corporation | 2.59 Million USD | 47.183% |
| Bioxytran, Inc. | 1.89 Million USD | 27.96% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2091.805% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 37.275% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 60.164% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 84.006% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -77.059% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 209.438% |
| Neutra Corp. | 52.18 Thousand USD | -2521.287% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 154.961% |
| PureTech Health plc | -167.19 Million USD | 100.818% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 658.565% |
| IXICO plc | -4.44 Million USD | 130.778% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 89.651% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.506% |
| CSL Limited | 10.52 Billion USD | 99.987% |
| Cellectis S.A. | -43.81 Million USD | 103.122% |